James Crenshaw, MD
Cardiovascular Disease · Jackson, TNNPI 1952396541
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Medtronic at 37.1% of the total. That places this record below the midpoint for cardiovascular disease clinicians in TN, where the typical reported total is $1,892.
Across 40 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$361
- E.r. Squibb & Sons, L.L.C.$135
- Novartis$100
- Amgen$75
- Pfizer$46
- Abiomed$39
- plus $217 from 10 others
Across 48 payments — averaging $16,468 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$651K
- Akcea Therapeutics, Inc.$111K
- Ionis Pharmaceuticals, Inc.$19K
- Boehringer Ingelheim$10K
What the payments were for
- Food & beverage$972100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $361 |
| E.r. Squibb & Sons, L.L.C. | 7 | $135 |
| Novartis | 7 | $100 |
| Amgen | 5 | $75 |
| Pfizer | 3 | $46 |
| Abiomed | 1 | $39 |
| Boston Scientific | 2 | $30 |
| Cordis US CORP. | 1 | $28 |
| Abbott | 1 | $27 |
| Edwards Lifesciences | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Shockwave Medical, Inc | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$183
- 3F$117
How this compares
$972 in reported general payments places this provider in the 40th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,112 | $891,985 |
| Repatha SureclickEvolocumab | 165 | $126,068 |
| EntrestoSacubitril/Valsartan | 60 | $69,494 |
| XareltoRivaroxaban | 66 | $67,584 |
| FarxigaDapagliflozin Propanediol | 38 | $32,489 |
| Praluent PenAlirocumab | 43 | $31,810 |
| JardianceEmpagliflozin | 38 | $25,905 |
| Metoprolol Succinate | 816 | $11,766 |
| Ranolazine ErRanolazine | 103 | $11,631 |
| BrilintaTicagrelor | 17 | $8,147 |
| ClopidogrelClopidogrel Bisulfate | 747 | $8,083 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 506 | $7,491 |
| Atorvastatin Calcium | 751 | $7,151 |
| Rosuvastatin Calcium | 378 | $5,173 |
| NexletolBempedoic Acid | 12 | $4,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $891,9851,112 claims |
| NovartisEntresto | $100 | $69,49460 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Jackson
- Adeyinka AgbetoyinJackson$112K
- Elliot KurbanJackson$68K
- Shahzad ShahJackson$15K
- Mohsin AlhaddadJackson$14K
- Alexander AlperovichJackson$13K
- Nirav PatelJackson$12K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.